{"url_path":"/sec/adma/8-k/2026-06-02/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-02","source_url":"https://www.sec.gov/Archives/edgar/data/1368514/0001140361-26-023705-index.html","accession_number":"0001140361-26-023705","cik":"0001368514","ticker":"ADMA","issuer_name":"ADMA BIOLOGICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1368514/0001140361-26-023705-index.html","primary_entity_key":"0001368514","primary_entity_name":"ADMA BIOLOGICS, INC."},"word_count":434,"has_tables":true,"body_markdown":"Item 5.07\n\nSubmission of Matters to a Vote of Security Holders\n\nADMA Biologics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on June 2, 2026. At the Annual Meeting, the following matters\nwere submitted to a vote of stockholders:\n\n1.\n\nThe election of two nominees to serve as Class I directors until the Company’s 2029 Annual Meeting of Stockholders and until such director’s successor is duly elected\nand qualified, or such director’s earlier resignation, removal or death;\n\n2.\n\nThe ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026; and\n\n3.\n\nThe approval of, on a non-binding, advisory basis, the compensation of the Company’s named executive officers (“Say-on-Pay”).\n\nAt the close of business on April 8, 2026, the record date for the determination of stockholders entitled to vote at the Annual Meeting, there were 232,324,283 shares of\nthe Company’s common stock outstanding and entitled to vote at the Annual Meeting. The holders of 199,267,547 shares of the Company’s common stock, $0.0001 par value per share, were represented virtually or by proxy at the Annual Meeting,\nconstituting a quorum.\n\nAt the Annual Meeting, (i) the two Class I directors were elected, (ii) the appointment of the Company’s independent registered public accounting firm for the fiscal\nyear ending December 31, 2026 was ratified, and (iii) the Say-on-Pay proposal was approved.\n\nProposal No. 1 — Election of the Class I\nDirectors\n\n \n\nThe vote with respect to the election of each of the directors was as follows:\n\nNominee\n\nFor\n\nWithheld\n\nBroker Non-Votes\n\nAlison C. Finger\n\n156,849,830\n\n19,376,842\n\n23,040,875\n\nEduardo Rene Salas\n\n171,947,523\n\nShares\n\n4,279,149\n\nShares\n\n23,040,875\n\nShares\n\nProposal No. 2 — Ratification of the\nAppointment of Independent Registered Public Accounting Firm\n\n \n\nThe vote with respect to the ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December\n31, 2026 was as follows:\n\nFor\n\nAgainst\n\nAbstain\n\n198,655,040\n\nShares\n\n329,056\n\nShares\n\n283,451\n\nShares\n\nProposal No. 3 — Approval of the Say-on-Pay\nProposal\n\n \n\nThe vote with respect to the approval of, on a non-binding, advisory basis, the compensation of the Company’s named executive officers was as follows:\n\nFor\n\nAgainst\n\nAbstain\n\nBroker Non-Votes\n\n168,169,866\n\nShares\n\n7,730,690\n\nShares\n\n326,116\n\nShares\n\n23,040,875\n\nShares\n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the\nundersigned hereunto duly authorized.\n\nJune 2, 2026\n\nADMA Biologics, Inc.\n\nBy:\n\n/s/ Adam S. Grossman\n\nName:\n\nAdam S. Grossman\n\nTitle:\n\nPresident and Chief Executive Officer"}